At this EULAR 2022 session, one expert explains why he believes refractory gout is caused by mismanagement and discussed ways around treatment obstacles.
Search results for: gout flare
Imaging Modalities in Gout: How to Use them in Clinical Practice
This EULAR 2022 session discussed the increasing role of imaging in the diagnosis of gout.
Treating to Target in Gout: The Trouble with Serum Urate
New analyses of treat to target in gout may lead to revisions in some guidelines.
Gout Experts Share Insights Into a Variety of Challenging Gout Scenarios
Although the diagnosis and treatment of gout are sometimes straightforward, practitioners encounter challenges in patients with atypical presentations, as well as those with medically complex situations or refractory disease. Here, gout experts share insights into some of these scenarios. Flare in Hospitalized Patients When not contraindicated, the 2020 ACR Guideline for the Management of Gout…
Another Way: RheumMadness 2022 DECT in Gout Scouting Report
Research has found dual-energy computed tomography (DECT) may be a non-invasive and cost-effective option to help rheumatologists more accurately diagnose gout.
Gout Management Recommendations from the ACR’s 2020 Guideline
The 2020 ACR Guideline for the Management of Gout is intended to provide guidance for the management of patients with gout, and includes recommendations on the indications for and optimal use of urate-lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations.1 The guideline includes 42 recommendations, of which 16 are strong….
Clinical Insights into Gout Management: Q&A with Dr. Tuhina Neogi
Gout affects more than 9.2 million adults in the U.S. and is the most common form of inflammatory arthritis. This condition and its complications are painful and potentially disabling with varying risk factors. It is characterized by symptoms that are usually sudden, with intense episodes of painful swelling in one or more joints, most often…
Tigulixostat Appears Promising for the Treatment of Gout
In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.
Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout
A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…
Pegloticase Proves Promising for Gout in Patients who Have Undergone Kidney Transplant
Patients who have undergone a kidney transplant and have high levels of serum uric acid symptomatic gout may benefit from treatment with pegloticase, according to a recent study.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 15
- Next Page »